# A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours

> **NCT03427073** · PHASE1 · TERMINATED · sponsor: **Almac Discovery** · enrollment: 20 (actual)

## Conditions studied

- Solid Tumors
- Ovarian Cancer

## Interventions

- **DRUG:** ALM201

## Key facts

- **NCT ID:** NCT03427073
- **Lead sponsor:** Almac Discovery
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-27
- **Primary completion:** 2017-03-13
- **Final completion:** 2017-03-13
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** to re-evaluate biomarker strategy for recruitment to Part 2
- **Last updated:** 2019-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03427073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03427073, "A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03427073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*